



February 7, 2012

MannKind to Present at Upcoming Conferences

VALENCIA, Calif.--(BUSINESS WIRE)--Feb. 7, 2012-- **MannKind Corporation (Nasdaq: MNKD)**, focused on discovering, developing and commercializing treatments for diabetes and cancer, announced today that it will present at upcoming conferences.

- The 14th Annual BioCEO Investor Conference on February 14, 2012 at 2:00 p.m. ET at the Waldorf-Astoria in New York, New York
- The Leerink Swann 2012 Global Healthcare Conference on February 15, 2012 at 9:00 a.m. ET at the Waldorf-Astoria in New York, New York

Interested parties can access a link to the live webcast of the presentations from the News & Events section of the Company's website at <http://www.mannkindcorp.com>.

About MannKind Corporation

MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes and cancer. Its lead product candidate, AFREZZA®, is in late stage clinical investigation for the treatment of adults with type 1 or type 2 diabetes for the control of hyperglycemia. MannKind maintains a website at www.mannkindcorp.com to which MannKind regularly posts copies of its press releases as well as additional information about MannKind. Interested persons can subscribe on the MannKind website to e-mail alerts that are sent automatically when MannKind issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the website.

Source: MannKind Corporation

MannKind Corporation
Matthew J. Pfeffer
Corporate Vice President and
Chief Financial Officer
661-775-5300
mpfeffer@mannkindcorp.com